guest ::
| Home > Publications database > EASIX-guided risk stratification for complications and outcome after CAR T-cell therapy with ide-cel in relapsed/refractory multiple myeloma. > print |
| Home > Publications database > EASIX-guided risk stratification for complications and outcome after CAR T-cell therapy with ide-cel in relapsed/refractory multiple myeloma. > print |
| 001 | 293957 | ||
| 005 | 20241113140630.0 | ||
| 024 | 7 | _ | |a 10.1136/jitc-2024-009220 |2 doi |
| 024 | 7 | _ | |a pmid:39379098 |2 pmid |
| 024 | 7 | _ | |a altmetric:169084721 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2024-02022 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Frenking, Jan Hendrik |0 P:(DE-He78)3f4df1d4b15ea8b1daad69322a01e26b |b 0 |e First author |u dkfz |
| 245 | _ | _ | |a EASIX-guided risk stratification for complications and outcome after CAR T-cell therapy with ide-cel in relapsed/refractory multiple myeloma. |
| 260 | _ | _ | |a London |c 2024 |b BioMed Central |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1728466607_19434 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a #EA:A360#LA:A360# |
| 520 | _ | _ | |a Chimeric antigen receptor (CAR) T-cell therapy has demonstrated significant benefits in the treatment of relapsed/refractory multiple myeloma (RRMM). However, these outcomes can be compromised by severe complications, including cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome (ICANS) and immune effector cell-associated hematotoxicity (ICAHT), predisposing for life-threatening infections.This retrospective observational study examined a total of 129 patients with RRMM who had received idecabtagene vicleucel (ide-cel) at two major myeloma centers in Germany and one center in the USA to assess the Endothelial Activation and Stress Index (EASIX) as a risk marker for an unfavorable clinical course and outcome after CAR T-cell therapy. EASIX is calculated by lactate dehydrogenase (U/L) × creatinine (mg/dL) / platelets (109 cells/L) and was determined before lymphodepletion (baseline) and at the day of CAR T-cell infusion (day 0). The analysis was extended to EASIX derivatives and the CAR-HEMATOTOX score.An elevated baseline EASIX (>median) was identified as a risk marker for severe late ICAHT, manifesting with an impaired hematopoietic reconstitution and pronounced cytopenias during the late post-CAR-T period. Patients with high EASIX levels (>upper quartile) were particularly at risk, as evidenced by an increased rate of an aplastic phenotype of neutrophil recovery, severe late-onset infections and ICANS. Finally, we found associations between baseline EASIX and an inferior progression-free and overall survival. Moreover, the EASIX at day 0 also demonstrated potential to serve as a risk marker for post-CAR-T complications and adverse outcomes.In conclusion, EASIX aids in risk stratification at clinically relevant time points prior to CAR T-cell therapy with ide-cel. Increased EASIX levels might help clinicians to identify vulnerable patients to adapt peri-CAR-T management at an early stage. |
| 536 | _ | _ | |a 311 - Zellbiologie und Tumorbiologie (POF4-311) |0 G:(DE-HGF)POF4-311 |c POF4-311 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de |
| 650 | _ | 7 | |a chimeric antigen receptor - CAR |2 Other |
| 650 | _ | 7 | |a cytopenia |2 Other |
| 650 | _ | 7 | |a immunotherapy |2 Other |
| 650 | _ | 7 | |a multiple myeloma |2 Other |
| 650 | _ | 7 | |a treatment related adverse event - trAE |2 Other |
| 650 | _ | 7 | |a idecabtagene vicleucel |0 8PX1X7UG4D |2 NLM Chemicals |
| 650 | _ | 7 | |a Receptors, Chimeric Antigen |2 NLM Chemicals |
| 650 | _ | 7 | |a Biological Products |2 NLM Chemicals |
| 650 | _ | 2 | |a Humans |2 MeSH |
| 650 | _ | 2 | |a Multiple Myeloma: therapy |2 MeSH |
| 650 | _ | 2 | |a Multiple Myeloma: immunology |2 MeSH |
| 650 | _ | 2 | |a Male |2 MeSH |
| 650 | _ | 2 | |a Female |2 MeSH |
| 650 | _ | 2 | |a Middle Aged |2 MeSH |
| 650 | _ | 2 | |a Immunotherapy, Adoptive: adverse effects |2 MeSH |
| 650 | _ | 2 | |a Immunotherapy, Adoptive: methods |2 MeSH |
| 650 | _ | 2 | |a Aged |2 MeSH |
| 650 | _ | 2 | |a Retrospective Studies |2 MeSH |
| 650 | _ | 2 | |a Adult |2 MeSH |
| 650 | _ | 2 | |a Receptors, Chimeric Antigen |2 MeSH |
| 650 | _ | 2 | |a Risk Assessment |2 MeSH |
| 650 | _ | 2 | |a Biological Products: therapeutic use |2 MeSH |
| 650 | _ | 2 | |a Treatment Outcome |2 MeSH |
| 650 | _ | 2 | |a Cytokine Release Syndrome: etiology |2 MeSH |
| 700 | 1 | _ | |a Zhou, Xiang |b 1 |
| 700 | 1 | _ | |a Wagner, Vivien |b 2 |
| 700 | 1 | _ | |a Hielscher, Thomas |0 P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f |b 3 |u dkfz |
| 700 | 1 | _ | |a Kauer, Joseph |b 4 |
| 700 | 1 | _ | |a Mai, Elias K |b 5 |
| 700 | 1 | _ | |a Friedrich, Mirco J |b 6 |
| 700 | 1 | _ | |a Michel, Christian S |b 7 |
| 700 | 1 | _ | |a Hajiyianni, Marina |b 8 |
| 700 | 1 | _ | |a Breitkreutz, Iris |b 9 |
| 700 | 1 | _ | |a Costello, Patrick |b 10 |
| 700 | 1 | _ | |a Nadeem, Omar |b 11 |
| 700 | 1 | _ | |a Weinhold, Niels |0 P:(DE-He78)66b39a79f3f922997656d7b902d324fb |b 12 |u dkfz |
| 700 | 1 | _ | |a Goldschmidt, Hartmut |b 13 |
| 700 | 1 | _ | |a Schmitt, Anita |b 14 |
| 700 | 1 | _ | |a Luft, Thomas |b 15 |
| 700 | 1 | _ | |a Schmitt, Michael |b 16 |
| 700 | 1 | _ | |a Müller-Tidow, Carsten |b 17 |
| 700 | 1 | _ | |a Topp, Max |b 18 |
| 700 | 1 | _ | |a Einsele, Hermann |b 19 |
| 700 | 1 | _ | |a Dreger, Peter |b 20 |
| 700 | 1 | _ | |a Munshi, Nikhil C |b 21 |
| 700 | 1 | _ | |a Sperling, Adam S |b 22 |
| 700 | 1 | _ | |a Rasche, Leo |b 23 |
| 700 | 1 | _ | |a Sauer, Sandra |b 24 |
| 700 | 1 | _ | |a Raab, Marc-Steffen |0 P:(DE-He78)1cb537e833afd985097ccfaddffb2ef3 |b 25 |e Last author |u dkfz |
| 773 | _ | _ | |a 10.1136/jitc-2024-009220 |g Vol. 12, no. 10, p. e009220 - |0 PERI:(DE-600)2719863-7 |n 10 |p e009220 |t Journal for ImmunoTherapy of Cancer |v 12 |y 2024 |x 2051-1426 |
| 856 | 4 | _ | |u https://inrepo02.dkfz.de/record/293957/files/e009220.full.pdf |
| 856 | 4 | _ | |u https://inrepo02.dkfz.de/record/293957/files/e009220.full.pdf?subformat=pdfa |x pdfa |
| 909 | C | O | |o oai:inrepo02.dkfz.de:293957 |p VDB |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 0 |6 P:(DE-He78)3f4df1d4b15ea8b1daad69322a01e26b |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 3 |6 P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 12 |6 P:(DE-He78)66b39a79f3f922997656d7b902d324fb |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 25 |6 P:(DE-He78)1cb537e833afd985097ccfaddffb2ef3 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-311 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Zellbiologie und Tumorbiologie |x 0 |
| 914 | 1 | _ | |y 2024 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b J IMMUNOTHER CANCER : 2022 |d 2023-08-19 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2023-08-19 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2023-08-19 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0320 |2 StatID |b PubMed Central |d 2023-08-19 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0501 |2 StatID |b DOAJ Seal |d 2023-05-02T08:46:44Z |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0500 |2 StatID |b DOAJ |d 2023-05-02T08:46:44Z |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b DOAJ : Anonymous peer review |d 2023-05-02T08:46:44Z |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2023-08-19 |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2023-08-19 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2023-08-19 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2023-08-19 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2023-08-19 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2023-08-19 |
| 915 | _ | _ | |a IF >= 10 |0 StatID:(DE-HGF)9910 |2 StatID |b J IMMUNOTHER CANCER : 2022 |d 2023-08-19 |
| 915 | _ | _ | |a Article Processing Charges |0 StatID:(DE-HGF)0561 |2 StatID |d 2023-08-19 |
| 915 | _ | _ | |a Fees |0 StatID:(DE-HGF)0700 |2 StatID |d 2023-08-19 |
| 920 | 2 | _ | |0 I:(DE-He78)A360-20160331 |k A360 |l KKE Mol. Hämatologie/Onkologie |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)A360-20160331 |k A360 |l KKE Mol. Hämatologie/Onkologie |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)C060-20160331 |k C060 |l C060 Biostatistik |x 1 |
| 920 | 0 | _ | |0 I:(DE-He78)A360-20160331 |k A360 |l KKE Mol. Hämatologie/Onkologie |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)A360-20160331 |
| 980 | _ | _ | |a I:(DE-He78)C060-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|